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Unseparated peripheral blood mononuclear cells (PBMCs) obtained from drug-naı ¨ve African
individuals living in a context of multi-infections and presenting with high viral load (VL), were
cultured in vitro and tested for their ability to produce antibodies (Abs) reacting with HIV-1 antigens.
Within these PBMCs, circulating B cells were differentiated invitro and produced IgG Abs against not
only ENV, but also GAG and POL proteins. Under similar experimental conditions, HAART treated
patients produced Abs to ENV proteins only. The in vitro antibody production by drug-naı ¨ve
individuals’ PBMCs depended on exogenous cytokines (IL-2 and IL-10) but neither on the
re-stimulation of reactive cells in cultures by puriﬁed HIV-1-gp160 antigen nor on the re-engagement
of CD40 surface molecules. Further, it was not abrogated by the addition of various monoclonal Abs
(mAbs) to co-stimulatory molecules. This suggests that the in vitro antibody production by drug-naı ¨ve
individuals’ PBMCs resulted from the maturation of already envelope and core antigen-primed,
differentiated B cells, presumably pre-plasma cells, which are not known to circulate at homeostasy. As
in vitro produced Abs retained the capacity of binding antigen and forming complexes, this study
provides pre-clinical support for functional humoral responses despite major HIV- and other tropical
pathogen-induced B cell perturbations.
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INTRODUCTION
HIV-infection in Africa presents some unique features
including diverse viral clades and clinical manifestations
of disease. The limited access to HAART and also the
presence of chronic tropical diseases induce profound
lymph node and germinal center disorganization. An
important issue in order to take care of these patients is to
determine if they are still capable of producing functional
HIV-speciﬁc antibodies (Abs), and—at large—functional
Abs to other pathogens.
HIV infection induces disturbances in cellular and
humoral immunity, both at the speciﬁc and non-speciﬁc
levels (Fauci et al., 1996). Typically, untreated HIV-
infected individuals experience disease progression
accompanied by hypergammaglobulinemia yet lack
speciﬁc neutralizing anti-HIV envelope glycoprotein Abs.
It is commonly held that a profound B cell dysfunction
is associated with HIV (Richard et al., 2002). Meanwhile,
there is an increasing body of evidence that certain
neutralizing Abs (NAbs) are instrumental in protection
against HIV infection, as demonstrated both at the
mucosal and the systemic level (Devito et al., 2000; Moja
et al., 2000). NAbs may indeed achieve protection in the
systemic compartment, at least in certain experimental
hosts (Mascola et al., 1999; Baba et al., 2000).
WehavepreviouslyshownthatHIV-infected,drug-naı ¨ve
AIDS patients living in Africa, and exposed to multiple
concurrent infections (Garin et al., 1997; Germani et al.,
1998; Begaud et al., 2003), exhibited diminished levels of
naı ¨ve and memory-blood B lymphocytes but augmented
levels of centro-germinative (CG), post-germinative blood
Bcells,andpre-plasmacellswhichareaberrantcellsinthe
periphery (Beniguel et al., 2004).
The present investigation aimed at examining whether
peripheral blood mononuclear cells (PBMCs) obtained
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AIDSandcomprisingofvarious Bcellssubsets—ofwhich
usually non-circulating B cells—could still produce HIV-
1-speciﬁc Abs. The study also aimed at examining some
characteristics of this in vitro Ab production (IVAP) to set
up a rationale for immune-interventions when available.
MATERIALS AND METHODS
Patients
African donors were HIV-positive patients from the
“Ho ˆpital Communautaire” of Bangui, Central African
Republic (CAR). The prevalence of HIV-infection in CAR
is estimated to be 12.9% of the adult population (http://
www.unaids.org; 2002). All donors enrolled in this study
were informed and consented to donate blood for research
purposes, according to the rules of the ad hoc Ethics
Committee set up by the Institut Pasteur in Bangui, in the
absence of a National Ethics Committee. None of the
blood donors were previously diagnosed with HIV
infection, and all were indeed antiretroviral drug-naı ¨ve.
For comparison of biological parameters, European
volunteer blood donors were also tested in this survey.
They consisted of 10 HIV-positive patients (Table I)
followed by the Department of Infectious Diseases at the
University Hospital in St-Etienne. Informed consent was
obtained from every patient according to the requirements
of the National French Ethics Committee. They were all
treated with antiretroviral drugs according to current
protocols. Each European patient was also monitored for
clinical and biological parameters predictive of disease
progression. Matched controls consisted of HIV-negative
African and European blood donors. Approximately 10ml
of heparinized blood was obtained for the present study.
Serology and Viral Load (VL) Determination
HIV serology was routinely followed in Bangui using the
Vironoctika HIV Uniform II plus O test (Organon
Teknika, Durham, NC). HIV serology in St-Etienne was
done with the HIV duo (Vidas Biome ´rieux, Marcy
L’Etoile, Lyon, France) and Enzygnost HIV1 þ 2
(Behring, Marburg, Germany). Plasma VL was deter-
mined using a PCR technique as previously described
(Bourlet et al., 2001).
PBMC Preparation
Plasma was removed by centrifugation at 1,500rpm/min
and stored at 2208C. PBMCs were isolated by density
gradient centrifugation (Lymphocyte Separation Medium,
Eurobio, Les Ulis, France). As the B cell phenotyping was
not performed in Bangui, 1 £ 106 PBMC were stored at
48C in Stabilcytee (BioErgonomics, St Paul, MN), for
approximately 2 months prior to be shipped in France and
labeled for ﬂow cytometry analysis.
PBMC Cultures
PBMCs were cultured in Iscove’s Modiﬁed Dulbecco’s
Medium (IMDM) culture medium (Biowhittaker,
Verviers, Belgique) supplemented with 10% endotoxin-
free heat-inactivated Fetal Calf Serum (FCS) (US14-901F;
BioWhittaker), 1% MEM amino acids solution (Sigma-
Aldrich, Dorset, UK), 1% MEM non-essentialamino acids
solution (Sigma), 1% Insulin–Transferin–Selenite med-
ium (Sigma) and 1% antibiotics (Antibiotic–Antimytotic
solution; Sigma) as described (Garraud et al., 1995). This
preparation will therefore be referred to as “complete
medium”. In order to allow cultured PBMCs to shed
membrane-bound Igs or immune complexes that could
interfere with speciﬁc assays, PBMC were rested by an
overnight incubation at 378C as already described
(Garraud et al., 2001). On the following day, PBMCs
were readjusted at 10
6 cells/ml in fresh cultured medium
TABLE I Major characteristics of the HIV
þ patients enrolled in the
study. (A) African patients, (B) European patients
Age CD4 VL
(A) African patients
1 F 30 nd 5.15
2 F 28 246 5.88
3 F 18 1117 nd
4 M 45 133 5.51
5 F 43 nd nd
6 M 33 65 nd
7 F 27 421 nd
8 M 33 23 5.88
9 F 30 445 5.4
10 F 22 nd 5.61
11 M 56 nd nd
12 F 20 854 nd
13 M 32 378 nd
14 F 24 702 nd
15 M 32 9 4.2
16 F 38 268 5.2
17 F 16 992 nd
18 M 39 456 5.4
19 F 28 128 nd
20 M 33 68 nd
21 F 28 854 nd
22 F 25 956 4.5
23 M 43 1332 5.6
24 F 38 611 5.15
(B) European patients
1 M 64 499 .1.7
2 M 44 303 3.81
3 F 49 759 .1.7
4 M 39 383 .1.7
5 M 31 650 4.52
6 M 46 439 .1.7
7 M 41 415 3.63
8 F 66 442 .1.7
9 M 45 322 .1.7
10 M 32 465 3.85
Mean CD4þ ¼ 502:9 ^ 403:2cells=ml: Mean VL ¼ 5:24: Mean CD4þ ¼ 468 ^
134cells=ml: Mean VL ¼ 2:6:
Notes: M and F stands for Male and Female; Age is expressed in years; CD4 count
is expressed in CD4
þ cells per ml ^SD; plasma viral load is expressed in log
(copies/ml).
nd: not determined.
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plate (Costar, NY).
PBMCs were then cultured in the presence or absence
of additional stimuli to favor the terminal differentiation
of B cells into Ig secreting cells. The following stimuli
were used alone or in combinations at predetermined
concentrations: (i) cytokines: IL-4 (Peprotech, Rocky
Hill, NJ); IL-2 (Peprotech); IL-10 (R&D Systems,
Minneapolis, MN) and TGF-b, all used at 20ng/ml.
(ii) Ag: HIV MN/LAI Ag gp160 (Aventis-Pasteur, Marcy-
L’Etoile, France), used at 0.1mg/ml; (iii) control cultures
were performed in the presence of cycloheximide (CHX)
(0.1mg/ml; Sigma) to prevent protein synthesis. Some
PBMC were also stimulated with 10ng/ml of soluble
CD40L molecule. Individual cultures were carried out for
3–12 days at 378Ci n5 %C O 2 humidiﬁed atmosphere.
Cell-free culture supernatants were stored at 2208C until
used in Ab detection assays.
To test for the binding capacity of in vitro-produced
anti-gp160 IgG Abs, individual 200ml supernatant
samples were incubated with puriﬁed recombinant
gp160 (used at 100ng as determined in a series of
preliminary experiments), for 3h at 378C, prior to Western
blotting (WB).
In an attempt to inhibit Ag presentation to B cells and/or
direct cell adhesion, PBMCs were cultured in 96-well
plates in the presence or absence of anti-CD54, anti-
CD18, anti-CD11c and anti-HLA-DR mAbs, or isotype
controls (Coulter-Immunotech, Marseille, France). These
monoclonal Abs (mAbs) were used at a predermined
concentration of 1mg/ml at the onset of the cultures.
Apoptosis Assays
In order to estimate ongoing apoptosis of cultured cells,
culture supernatants (100ml) were tested a posteriori for
the presence of NMP 41/7 (Nuclear Matrix Protein, a
protein released by cell death) in culture supernatants,
usingacommercialNMPELISA(Calbiochem,SanDiego,
CA). It has been described that the presence of NMP41/7
marker, in cell culture supernatants, was correlated to
cell DNA fragmentation and FAS-Ligand production
(Baize et al., 1999).
Ab Production Analysis
For the broad detection of anti-HIV IgG Abs, plasma
(dilution 1/90) or culture supernatants (dilution 1/9) were
tested by WB (HIV BLOT 2.2, Abbott, Rungis, France)
according to the manufacturer’s protocol. Brieﬂy, samples
were incubated overnight on speciﬁc nitrocellulose blots
in the appropriate buffer. Positive and negative controls
were high anti-HIV Ab titer serum and HIV-negative
serum, respectively. After several washes, blots were
incubated 30min with a phosphatase alkaline conjugated
anti-IgG and 15min with the appropriate substrate.
Additionally, total IgG in culture supernatants were
analyzed using ELISAs performed in 96-well MaxiSorpe
plates (NUNC, Roskilde, Denmark) as previously
described (Garraud et al., 1995). IgG concentration was
extrapolated from a reference curve generated by assaying
dilutions of a pool of plasma specimens from blood donors
whose IgG concentrations were determined by an
immunonephelometric technique (Mininephe, The Bind-
ing Site, Oxford, UK).
PBMC Phenotyping
Standard T (CD4
þ) cell phenotyping was performed at the
Institut Pasteur in Bangui using 100ml of fresh whole
blood labeled with a mAb (anti-CD4, Becton Dickinson
Immunocytometry Systems, San Jose, CA) as described
(Menard et al., 2003). Lymphocyte subsets were routinely
analyzed on a FACSCalibur ﬂow cytometer (Becton
Dickinson Immunocytometry Systems).
As B cell phenotyping was not routinely performed in
Bangui, PBMC were stored in Stabilcytee until the
staining. After extensive washings in PBS with 10% FCS,
PBMC ð0:5 £ 106Þ were labeled with RPECy5 labeled
anti-CD20 mAb (DAKO, Copenhagen, Denmark). Brieﬂy,
0:5 £ 106 cells were stained with the mAb for 45min on
ice. Afterwards, the cells were washed in PBS/10% FCS
and ﬁxed in PBS containing 4% paraformaldehyde. Flow
cytometry was performed on the following day using a
FacsVantage-SF BD and the CellQuest-Proe software
(Becton-Dickinson).
Statistical Analysis
Means ^ standard deviations (SD) of total IgG in
individual cultures were compared by means of the
Wilcoxon test (Statviewe, Cary, NJ).
RESULTS
Characteristics of the Blood Donors
The mean CD4
þ T cell count ^ SEM was 502:9 ^
403:2cells=mlf o rH I V
þ African donors and 913 ^
66cells=ml for HIV
2 African donors. The % mean of
CD20
þ B cell count ^ SEM was 4:9 ^ 0:7 for the HIV
þ
African donors and 6:7 ^ 0:6 for HIV
2 African donors.
As expected, the plasma VL was high for drug-naı ¨ve
African patients. It ranged from 10,000 to more than
800,000 copies/ml. For HAART-European patients,
plasma VL was controlled by antiretrovirals and ranged
from less than 50 to 50,000 copies/ml, with 6 patients
having less than 50 copies/ml (Table I).
Ig Production In Vitro
PBMCs from HIV
þ and HIV
2 African donors produced
equally large amounts of Ig in vitro (mean IgG production
were 0.115mg/l) as tested by ELISA. This IVAP was not
statistically augmented by exogenous cytokines IL-2 and
IL-10 and/or by recombinant HIV-gp160. As previously
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þ individuals was
detected as early as day 3 whereas maximum production
was observed after a 12 day culture (Cognasse et al.,
2003). This production was abrogated by CHX, indicating
it was de novo protein synthesis.
Speciﬁc Ab Production In Vitro by Peripheral Blood
B Cells from HIV
1 Individuals
PBMCsfrom14drug-naiveAfrican HIV
þdonors(TableI;
(1–14) were cultured in vitro for 12 days in the absence
of or presence of exogenous stimuli, IL-2 þ IL-10 or
HIV-1-gp160 Ag. In the vast majority (12/14) of
individual cultures, there was a spontaneous production
of anti-HIV IgG Abs, which was fairly augmented by
addition of IL-2 and IL-10 at the onset of the cultures.
For the two other individual cultures, a spontaneous Abs
production could also be detected by WB but was not
augmented by IL-2 and IL-10. In the 14 cultures, no
speciﬁc anti-gp160 Ab production was detected when
HIV-gp160 was added at the onset of the cultures. These
data are summarized in Table IIA. Thus the overall proﬁle
of IVAP in drug-naı ¨ve HIV-infected Africans’ PBMC was
a spontaneous Ab production which was augmented at
least in terms of antigenic speciﬁcities of Ab by IL-2 and
IL-10 (Fig. 1A). Of important note, soluble CD40L did not
prove to augment IVAP under these conditions.
Characteristically, the speciﬁc in vitro induced Abs
could recognize blotted Ags corresponding to gp160,
gp41 (ENV-), p24, p17 (GAG-) and p66, p51 and p31
(POL-proteins). This broad distribution proﬁle of Ab
speciﬁcities was observed in all 14 productive cultures.
In contrast, when PBMCs from HAART-treated patients
(Table IB) were cultured, three distinct proﬁles of IVAP
could be observed. In 2/10 individual cultures therewas no
production of Ab. In the other 8/10 cultures, there was a
detectable spontaneous Ab production against ENV Ag.
This production could be augmented by IL-2 and IL-10 in
3/8 cases but could not in the other 5/8 cases, 4 of these 5
corresponding to individual cultures of PBMCs from
donors with less than 50 mRNA copies/ml of plasma.
These data are summarized in Table IIB. The three
individual cultures where IVAP was augmented by IL-2
and IL-10 were performed using PBMCs from donors
with more than 2,500 mRNA copies/ml of plasma. Of
important note, 8/8 productive individual cultures
contained Abs which could recognize blotted Ags
corresponding to gp160 only, and only 1/8 combined a
mixture of anti-p31 (POL-protein) and anti-gp160 (ENV-
protein) and only 1/8 combined a mixture of anti-p24
(GAG-protein) and anti-gp160 Abs (Fig. 1).
The kinetics of Ab production was next assayed in a
novel series of cultures. This showed that Ab production
was detectable in culture supernatants as early as day 3, in
contrast to what is generally observed in PBMC cultures
from HIV
þ, but treated, donors.
Exogenous HIV-gp160 Extinguishes Spontaneous
Ab Production in HIV
1 Patients
In the majority of the culture systems described so far,
addition of a relevant stimulating Ag was required
for PBMCs to produce Ag-speciﬁc Abs in vitro (Garraud
et al., 1996). A stated above, “spontaneous” production of
Ag-speciﬁc Abs was observed in the absence of
stimulating Ag (e.g. recombinant gp160). Rather, in the
presence of Ag, the Ab production was abolished, an
observation which was made in every individual culture
(Fig. 1). As Ag overstimulation can induce apoptosis in
B cells, we tested a posteriori for the presence of
NMP41/7 in every culture supernatant. No evidence of
apoptosis or at least cell death was detected in any
individual culture.
We next tested for the possibility that speciﬁc anti-
gp120/160 Abs were released in culture supernatants
earlier than usual when naı ¨ve B cells undergo the
complete pathway of cell differentiation in vitro.
An indirect approach consisted of testing for the capacity
of invitro-produced Abs to make immune complexes with
Ag. Culture supernatants clearly showing spontaneous
Ab production were incubated a posteriori with
recombinant gp160 for 3h. This operation led to the
complete adsorption of anti-gp120/160 Abs in every
culture supernatant tested as can be seen in Fig. 1B.
TABLE II Antigenic speciﬁcities of the Ab produced by PBMC in vitro
IVAP in individual PBMC cultures in drug-naı ¨ve Africans IVAP in individual PBMC cultures in HAART-Europeans
Additional stimulus Additional stimulus
Antigen reactivity CHX ns IL-2 IL-10 HIV-1 gp160 CHX ns IL-2 IL-10 HIV-1 gp160
gp160 0/14 14/14 14/14 0/14 0/10 8/10 8/10 0/10
p66 0/14 1/14 7/14 1/14 0/10 0/10 0/10 0/10
p51 0/14 1/14 5/14 1/14 0/10 0/10 0/10 0/10
gp41 0/14 0/14 3/14 0/14 0/10 0/10 0/10 0/10
p31 0/14 0/14 6/14 0/14 0/10 0/10 1/10 0/10
p24 0/14 2/14 3/14 2/14 0/10 0/10 1/10 0/10
p17 0/14 0/14 1/14 0/14 0/10 0/10 0/10 0/10
Note: The Ab production in three culture conditions was estimated according to WB in the two groups of patients. The number of patients producing the speciﬁc Ab are
indicated. ns stands for non-stimulated PBMC.
L. BE ´NIGUEL et al. 124In contrast, anti-GAG and anti-POL proteins remained
unchanged.
Differential Intercellular Cooperation Affecting
Spontaneous Speciﬁc Ab Production In Vitro
The above reported data showed that: (i) HIV
þ African
individuals’ PBMCs produced anti-HIVAb, against ENV
proteins but also against GAG and POL proteins; (ii) such
Abs, characterized as IgG, were functional since they
bound exogenous gp160; (iii) in the majority of individual
cultures, this Ab production was augmented by exogenous
IL-2 and IL-10. We next examined the role of intercellular
molecular events between lymphocytes and other cell
types in PBMCs from HIV
þ patients. PBMCs from 10
Africans (Table I, 14–24) were incubated with a cocktail
of anti-leukocyte adhesion molecules (i.e. anti-CD54,
anti-CD18, anti-CD11c, and anti-HLA-DR), in the
presence or absence of IL-2 and IL-10 and in the presence
or absence of gp160. The mAb cocktail was added at the
onset of the 12-day PBMC culture. Spontaneous anti-
ENV, as well as anti-POL and anti-GAG, proteins
remained unaffected in every individual culture. Although
it cannot be excluded that mAbs were insufﬁcient in
amounts, or that repetitive addition of this cocktail over
time would have been necessary, or that other inter-
cellular Ag speciﬁcities would have been of greater effect,
those experiments suggest that spontaneous Ab production
in vitro by HIV
þ individuals’ PBMCs is relatively
independent of Ag presentation (at least by non B-cells),
but is dependent on certain accessory cell-derived soluble
factors such as cytokines. In a limited number of
experiments, similar results were obtained when mono-
cytes were depleted from PBMCs by adhesion to plastic
prior to the culture steps (data not shown).
DISCUSSION
Early in the AIDS epidemic, one commonly reported
biological disturbance was hypergammaglobulinemia.
Spontaneous production of Ig of diverse, but often
irrelevant, speciﬁcities, has been recorded when PBMCs
of HIV-infected individuals were examined in short- or
longer-term cultures (Amadori et al., 1988; Vendrell et al.,
1991). The African environment of concurrent infections
may impact humoral responses at large, as shown by total
Ig production in HIV
þ and HIV
2 donors. This is related to
observations of immune activation in a tropical environ-
ment (Lukwiya et al., 2001).
Observations over time have also been challenged with
the considerable progress achieved in managing the
patients, such as HAART and consistent reduction of VL
(Opravil et al., 2002). The machinery involved in such Ab
production dysfunction, however, most probably resides
in the LNs.
Our studied population comprised of African blood
donors unaware of their HIV
þ status although they
displayed characteristics of AIDS infection as they were
recruited on the basis of the WHO classiﬁcation for adult
AIDS in Africa (Greenberg et al., 1997).
We previously shown—in the same African popu-
lation—that HIV
þ patients displayed an abnormal
circulating blood B cell phenotype. Within the circulating
FIGURE 1 (A) Speciﬁcity assay. This ﬁgure shows HIV blots of PBMC culture supernatants for HIV
þ drug-naı ¨ve and HAART-treated patients in
various culture conditions: “ns” (non-stimulated) stands for PBMC in the absence of exogenous stimulus; “IL-2, IL-10” stands for PBMC stimulated by
IL-2 and IL-10; “gp160” stands for PBMC cultured in the presence of HIV-1 gp160. C þ stands for the positive-control; C 2 stands for the negative-
control. A typical drug-naı ¨ve proﬁle are presented; 3 Ab proﬁle for HAART-treated patients are presented. (B) Ag-binding function assay. Supernatants
of individual cultures of 3 drug-naı ¨ve patients are indicated. (1) Stands for the supernatant of PBMC stimulated by IL-2 and IL-10; (2) represents the
same supernatants after a 3h incubation with an excess of HIV-1 gp160. C þ stands for the positive-control; C 2 stands for the negative-control.
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(CD20
þ/CD77
þ, sIgM
2 sIgG
2 sIgA
2 sIgD
þ) CG and
(CD20
þ/CD38
þ CD138
þ) post-CG B cells usually
restricted to lymph nodes or equivalent secondary
lymphoid organs (Beniguel et al., 2004). In general, at
homeostasis, CG B cells are prone to apoptosis unless they
(i) encounter speciﬁc Ag; (ii) receive a CD40/CD40L
signal; (iii) receive activated T cell-mediated signals;
and/or (iv) are in contact with follicular dendritic cells
which provide Ag stimulation and other cognate and
secretory signals (Defrance et al., 2002).
In the present study, we questioned whether untreated
HIV
þ African patients’ peripheral B cells were able to
differentiate invitro and produce anti-HIV Abs, as those B
cells comprised of numerous CG and post-CG cells which
are usually prone to apoptosis, along with naı ¨ve and
memory B cells (which can be rather easily differentiated
in vitro). As there was no evidence of cell death in the
cultures, it cannot be excluded that most of those cells,
which were prone to apoptosis, died earlier on at the time
of the 24h resting period preceding the culture. Cultured
cells could produce fair levels of anti-HIV Abs in the
presence of survival signals such as IL-2 and IL-10 but did
not necessitate the re-engagement of CD40 and the re-
exposure to virus-derived Ags. This strongly suggest that
at least one major sub-population of B cells prone to
differentiate terminally were in fact already differentiated
and matured in such a manner that they produced not only
anti-ENV but also anti-GAG and POL-Abs. This
observation was strengthened by the observation that the
terminal maturation during the IVAP process was
independent on costimulatory molecules. It is thus very
likely that this population of Bcellscouldcomprise of pre-
plasma cells, whose % was elevated, an observation
already made by Fournier et al. (2002). Pre-plasma cells
do not express CD40, and would thus be unsensitive to
exogeneously supplied soluble CD40L signals.
Interestingly, our results indicate that B cell priming of
populations able to differentiate in vitro has occurred
in vivo. Indeed, these B cells have been likely primed by
surface Ag—as expected—but also by core Ag—which
means that at least some subsets of B cells in cultures have
met their epitope processed by an APC in vivo. Ags other
than ENV,i.e. GAG and POL are internal Ags and must be
processed or exposed (cell/virus lysis) for subsequent
presentation to the relevant Ag-reactive B cell. This
hypothesis was supported by the blocking studies which
aimed at interrupting intercellular cooperation. Our results
do not exclude the possibility that speciﬁc Ab production
can be affected by exogenous- or accessory-cell derived-
stimuli such as cytokines [24] along with IL-2 and IL-10
are two cytokines which affect almost all the activation
and differentiation steps of B lymphocytes especially their
maturation (Banchereau and Rousset, 1992), and rescue
germinal center-B cells from apoptosis (Levy and Brouet,
1994). The role of accessory- or B cells derived-IL-6 and
-TNF-a was found to be critically important; we did not
test for the addition of NAbs to IL-6 or TNF-a in
individual cultures since it is well established by others
and ourselves that this affects all Ab production in vitro in
most individual culture conditions (Garraud et al., 1996;
Fournier et al., 2002).
Of note, it is assumed that most Ag-reactive B cells
recognize the native form of the envelope gp120/160 Ag,
exposed by a cell-free or a cell-bound virus. We show here
that patients’ blood B lymphocytes in uncontrolled HIV
infection (no-antiviral therapy) were capable of producing
in vitro Abs against various HIV Ags unlike the majority
of patients with controlled viremia. Our data is consistent
with other published studies (Zamarchi et al., 2002) since
there is not stricto sensu a deﬁned correlation between the
initial VL and the capacity to produce Abs. We propose
instead that this parameter parallels the length of exposure
to the virus and/or the absence of therapeutic control.
We report here that HIV-infected individuals—even
AIDS patients with disorganized lymph node machinery
(Legendre et al., 1998)—can produce Abs reactive to HIV
envelope Ags which—at least in an in vitro model—bind
their cognate Ags, and possibly also against Ags from
concurrent infections (ongoing experiments). Patients
seem thus retain the capacity of developing certain Ab
responses. This property could be appropriately targeted
by immuno-interventions against HIV but also apportu-
nistic and/or concurrent infections.
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